Skip to content

Halozyme Therapeutics HALO Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$150.05M+27.1%$175.23M+27.9%$165.16M+77.1%$118.1M+53.7%
$4.22M+57.1%$3.3M+24.5%$2.7M+3.8%$2.7M+3.8%$2.69M+10.0%
$16.64M+55.9%$16.57M+44.6%$12.16M-3.3%$12.16M+28.4%$10.67M+8.1%
$180.08M+16.8%$219.03M+22.7%$178.6M+54.8%$99.71M+78.7%$154.22M+19.2%
$3.74M+294%$1.43M-53.2%$3.03M+99.7%$1.56M-39.5%$950K-73.2%
-$2.88M+96.8%-$741.79M$201.61M+220%-$90.42M-9.4%
-$1.61M+51.4%-$22.4M-221%-$298.97M-3,253%-$3.32M-579%
$175.59M+190%$357.8M+1,167%-$114.47M-593%$60.48M+30.7%
$176.34M+15.0%$217.6M+24.0%$175.57M+54.2%$98.15M+84.4%$153.27M+21.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Halozyme Therapeutics generate?
Halozyme Therapeutics (HALO) generated $677.4M in operating cash flow over the trailing twelve months.
What is Halozyme Therapeutics's free cash flow?
After $9.8M of capital expenditures, Halozyme Therapeutics's free cash flow was $667.7M over the trailing twelve months, up 34.7% year over year.
Where does Halozyme Therapeutics's cash flow data come from?
Every line is extracted from Halozyme Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.